VIPoma medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 3: Line 3:
{{CMG}}{{AE}}{{MSI}}{{PSD}}
{{CMG}}{{AE}}{{MSI}}{{PSD}}
==Overview==
==Overview==
Initial treatment in patient with VIPoma is prompt [[Fluid replacement therapy|replacement of fluid]] and correction of [[electrolyte imbalance]] and [[Acid-base disturbances|acid-base disturbance]].<ref name="sp">Vinik A. Vasoactive Intestinal Peptide Tumor (VIPoma) [Updated 2013 Nov 28]. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: http://www.ncbi.nlm.nih.gov/books/NBK278960/</ref>
Initial treatment in patient with VIPoma is prompt [[Fluid replacement therapy|replacement of fluid]] and correction of [[electrolyte imbalance]] and [[Acid-base disturbances|acid-base disturbance]]. [[Sandostatin|Somatostatin]] analogues like short acting [[octreotide]] is useful for controlling [[diarrhea]] by blocking the release of [[Vasoactive intestinal peptide|VIP]]. [[Octreotide]] is later replaced by longer acting depot preparation of somatostatin analogues like [[sandostatin]] or [[lanreotide]].


==Medical Therapy==
==Medical Therapy==

Revision as of 20:19, 19 January 2018

VIPoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating VIPoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

VIPoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of VIPoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on VIPoma medical therapy

CDC on VIPoma medical therapy

VIPoma medical therapy in the news

Blogs on VIPoma medical therapy

Directions to Hospitals Treating VIPoma

Risk calculators and risk factors for VIPoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3]

Overview

Initial treatment in patient with VIPoma is prompt replacement of fluid and correction of electrolyte imbalance and acid-base disturbance. Somatostatin analogues like short acting octreotide is useful for controlling diarrhea by blocking the release of VIP. Octreotide is later replaced by longer acting depot preparation of somatostatin analogues like sandostatin or lanreotide.

Medical Therapy

Initial treatment

Medical management

  • Somatostatin analogues like short acting octreotide is useful for controlling diarrhea by blocking the release of VIP.
  • Octreotide is later replaced by longer acting depot preparation of somatostatin analogues like sandostatin or lanreotide.
  • Steroids are used in diarrhea of VIPoma refractory to somatostatin.[1]
  • Initial Management
    • Preferred regimen (1) : Octreotide 50-100mcg q8h initially
  • Maintenance dosage
    • Preferred regimen (1): Sandostatin 20 mg IM every 4 weeks Lanreotide (120mg subQ every 4 weeks). (OR)
    • Preferred regimen (2): Lanreotide 120mg subcutaneously every 4 weeks.
  • Refractory cases
    • Preferred regimen (1): Prednisone 60 mg IM q24 for 1 week.
    • Preferred regimen (2): Sunitinib 37.5 mg PO q24h.

Medical management of advanced local or metastatic disease

  • There has been limited use of chemotherapy in patients with VIPoma. However, streptozocin based chemotherapy is considered best in the management of advanced local or metastatic disease.
  • Most successful and favourable combination regimen of chemotherapy is streptozocin with doxorubicin together with somatostatin analogues.
  • 5-FU can be used as alternative to doxorubicin in patients with who have contraindications to doxorubucin.[2]
  • Sunitinib (37.5 mg oral once a day) a tyrosin kinase inhibitor has some evidence of symptomatic and biochemical control in somatostatin analogue resistant VIPoma.[3][4]
  • Other molecular targeted therapy undergoing research for treatment are Everolimus (mTOR inhibitor) and Bevacizumab ( anti-VEGF monoclonal antibody).[5]

References

  1. O'Dorisio TM, Mekhjian HS, Gaginella TS (1989). "Medical therapy of VIPomas". Endocrinol Metab Clin North Am. 18 (2): 545–56. PMID 2545444.
  2. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R; et al. (2004). "Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas". J Clin Oncol. 22 (23): 4762–71. doi:10.1200/JCO.2004.04.024. PMID 15570077.
  3. Dimitriadis GK, Weickert MO, Randeva HS, Kaltsas G, Grossman A (2016). "Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours". Endocr Relat Cancer. 23 (9): R423–36. doi:10.1530/ERC-16-0200. PMID 27461388.
  4. Zhang J, Francois R, Iyer R, Seshadri M, Zajac-Kaye M, Hochwald SN (2013). "Current understanding of the molecular biology of pancreatic neuroendocrine tumors". J Natl Cancer Inst. 105 (14): 1005–17. doi:10.1093/jnci/djt135. PMID 23840053.
  5. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992). "Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma". N Engl J Med. 326 (8): 519–23. doi:10.1056/NEJM199202203260804. PMID 1310159.


Template:WikiDoc Sources